Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 20

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 20
---
 TELI Common Stock issued as the consideration will not be registered for trading under the Securities Act.

In addition to
the Merger Consideration, Erez Aminov and Bayshore Trust, shareholders of TELI, hold 4,250,000 and 10,000,000 warrants, respectively,
to purchase TELI Common Stock (the “Warrants”). The Warrants are exercisable upon FDA acceptance of an Investigational New
Drug (IND) application for Telomir- at $2.00 per share, for a period of 10-years. At Closing, the Warrants will be converted to warrants
to purchase Telomir Common Stock at similar terms as the Warrants.

Reasons for the Merger (see page 28)

The TELO Board considered various reasons for the Merger, as described later in this proxy statement under the section titled “ The Merger—Background of the Merger.”

Fairness Opinion and Valuation Reports of Moore Financial Consulting (page 31)

In September 2025, TELO retained Moore, as a financial advisor in connection with the Merger to conduct a valuation of TELO and TELI, and determination of the fairness of the Merger. In arriving at its opinion, Moore, among other things: (i) reviewed certain publicly available business and financial information concerning TELO and TELI and the industries in which they operate; (ii) analyzed TELO’s share pricing as traded on the Nasdaq; (iii) reviewed certain internal financial analyses and forecasts prepared by TELO’s and TELI’s finance departments, delivered to Moore through written materials including Excel sheets, and orally, in several meetings and discussions throughout the valuation process; and (iv) performed such other financial studies and analyses and considered such other information as Moore deemed appropriate for the purposes of its opinion. The forecasts were provided to Moore in October 2025. Additionally, TELI presented forecasts of the anticipated demand over the next few years for its pharmaceutical products. This included the expected prevalence of breast cancer and age-related across certain geographic and existing treatment gaps within this field. In addition to the above, Moore held discussions with certain members of the management of TELO and TELI about the Merger, and the past and current business operations of TELO and TELI, the financial condition and future prospects and operations of TELO and TELI, and certain other matters Moore believed necessary or appropriate for its inquiry.

For a summary of Moore’s fairness opinion and